Moderna is set to expand its US manufacturing capabilities through the onshoring of drug product manufacturing to its present Moderna Technology Center – MTC located Norwood, Massachusetts, in a move that involves an investment of over $140m.
By way of this onshoring, the company is now going to operate complete end-to-end mRNA medicine manufacturing throughout the country.
It is anticipated to strengthen the network of Moderna in the US by way of supporting commercial and also clinical supply.
It is well to be noted that the initiative goes on to form part of the continued investment of the company in the US-based infrastructure, which is aimed at establishing a manufacturing platform so as to support the present portfolio of mRNA therapies as well as vaccines.
Since partnering with the US government by way of Operation Warp Speed, the mRNA platform from Moderna has led the way when it comes to biomedical innovation throughout the autoimmune disorders, cancer, and infectious diseases, as well as rare diseases.
Stephane Bancel, the CEO of Moderna, stated that through onshoring drug product manufacturing to their campus in Massachusetts’s Norwood, they have gone on to accomplish the complete manufacturing loop under one roof in the US.
She added that as an American company that is committed to building as well as producing in America, they are indeed proud to make their domestic footprint robust while at the same time bringing certain meaningful new jobs for the community.
It is well to be noted that the construction of the new facility has already begun, with completion targeted for the first half of 2027 itself.
The fact is that this investment is going to generate numerous skilled biomanufacturing jobs.
Apparently, in 2025, Moderna got $590m in funding from the US Department of Health and Human Services -HHS so as to speed up the development of pandemic influenza vaccines that are mRNA-based.
The initiative was seen as a part of a much broader effort so as to enhance the preparedness of the country for certain future infectious diseases.
